New hope for rare cancer: experimental drug targets tough tumors
NCT ID NCT06893783
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests a drug called tarlatamab in 60 adults with a rare, advanced cancer called extrapulmonary neuroendocrine carcinoma that has come back after standard chemotherapy. The drug works by helping the immune system attack cancer cells. The main goal is to see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS (NEC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
Yonsei Severance Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.